Rebecca K Viscusi

Interests

No activities entered.

Courses

Scholarly Contributions

Chapters

• Neumayer, L., & Viscusi, R. K. (2017). Assessment and Designation of Cancer Stage. In The Breast: Comprehensive Management of Benign and Malignant Disease(pp 531-554). Philadelphia, PA: Elsevier Inc.

Journals/Publications

• Chalasani, P., Segar, J., Pandey, R., Nagle, R. B., Lebeau, L. G., MacKerricher, W., Viscusi, R. K., Gonzalez, V., Schroeder, J. A., Livingston, R. B., & Baker, A. F. (2017). Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma. Breast Cancer Research.
• Goyal, U., Skrepnik, T., Davuluri, R., Ley, M., Chalasani, P., Viscusi, R. K., Lebeau, L. G., Livingston, R. B., Cui, H., & Gonzalez, V. J. (2017). Concurrent capecitabine and radiation therapy for high-risk breast cancer. Oncomedicine.
• Valencia, O. M., Samuel, S. E., Viscusi, R. K., Riall, T. S., Neumayer, L. A., & Aziz, H. (2017). The Role of Genetic Testing in Patients With Breast Cancer: A Review. JAMA surgery, 152(6), 589-594.
  More info

  In the United States from 2009 to 2013, the incidence of breast cancer was the highest of any cancer and the death rate was second to that of lung cancer. Approximately 5% to 10% of breast cancers are inheritable.
• Chalasani, P., Segar, J., Pandey, R., Nagle, R., LeBeau, L., MacKerricher, W., Viscusi, R. K., Gonzalez, V., Schroeder, J., Livingston, R. B., & Baker, A. F. (2016). Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma. Breast Cancer Research.
• MacKerricher, W., LeBeau, L., & Viscusi, R. K. (2016). Subtyping and Survival of Invasive Ductal Carcinoma among Hispanic and Non-Hispanic White Women in Tucson, Arizona. American Journal of Clinical Pathology, 146.
• McCrary, H. C., Krate, J., Savilo, C. E., Tran, M. H., Ho, H. T., Adamas-Rappaport, W. J., & Viscusi, R. K. (2016). Development of a fresh cadaver model for instruction of ultrasound-guided breast biopsy during the surgery clerkship: pre-test and post-test results among third-year medical students. American journal of surgery, 212(5), 1020-1025.
  More info

  The aim of our study was to determine if a fresh cadaver model is a viable method for teaching ultrasound (US)-guided breast biopsy of palpable breast lesions.
• Miller, R., Ho, H., Ng, V., Melissa, T., Rappaport, D., Adamas-Rappaport, W., Dandorf, S. J., Dunleavy, J., Viscusi, R. K., & Amini, R. (2014). Introducing a fresh cadaver model for ultrasound-guided central venous access training in undergraduate medical education.. Western Journal of Emergency Medicine, 17(3), 362-6.
  More info

  Approximately 2.5 hours spent on project for 2015
• Park, J. W., Liu, M. C., Yee, D., Yau, C., van 't Veer, L. J., Symmans, W. F., Paoloni, M., Perlmutter, J., Hylton, N. M., Hogarth, M., DeMichele, A., Buxton, M. B., Chien, A. J., Wallace, A. M., Boughey, J. C., Haddad, T. C., Chui, S. Y., Kemmer, K. A., Kaplan, H. G., , Isaacs, C., et al. (2016). Adaptive Randomization of Neratinib in Early Breast Cancer. The New England Journal of medicine, 375(1), 11-22.
  More info

  The heterogeneity of breast cancer makes identifying effective therapies challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or III breast cancer, evaluated multiple new agents added to standard chemotherapy to assess the effects on rates of pathological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time of surgery).
• Rugo, H. S., Olopade, O. I., DeMichele, A., Yau, C., van 't Veer, L. J., Buxton, M. B., Hogarth, M., Hylton, N. M., Paoloni, M., Perlmutter, J., Symmans, W. F., Yee, D., Chien, A. J., Wallace, A. M., Kaplan, H. G., Boughey, J. C., Haddad, T. C., Albain, K. S., Liu, M. C., , Isaacs, C., et al. (2016). Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. The New England Journal of medicine, 375(1), 23-34.
  More info

  The genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively randomized trial to screen multiple experimental regimens in combination with standard neoadjuvant chemotherapy for breast cancer. The goal is to match experimental regimens with responding cancer subtypes. We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with carboplatin.
• DeMichele, A., Yee, D., Berry, D. A., Albain, K. S., Benz, C. C., Boughey, J., Buxton, M., Chia, S. K., Chien, A. J., Chui, S. Y., Clark, A., Edmiston, K., Elias, A. D., Forero-Torres, A., Haddad, T. C., Haley, B., Haluska, P., Hylton, N. M., Isaacs, C., , Kaplan, H., et al. (2015). The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(13), 2911-5. doi:10.1158/1078-0432
  More info

  The many improvements in breast cancer therapy in recent years have so lowered rates of recurrence that it is now difficult or impossible to conduct adequately powered adjuvant clinical trials. Given the many new drugs and potential synergistic combinations, the neoadjuvant approach has been used to test benefit of drug combinations in clinical trials of primary breast cancer. A recent FDA-led meta-analysis showed that pathologic complete response (pCR) predicts disease-free survival (DFS) within patients who have specific breast cancer subtypes. This meta-analysis motivated the FDA's draft guidance for using pCR as a surrogate endpoint in accelerated drug approval. Using pCR as a registration endpoint was challenged at ASCO 2014 Annual Meeting with the presentation of ALTTO, an adjuvant trial in HER2-positive breast cancer that showed a nonsignificant reduction in DFS hazard rate for adding lapatinib, a HER-family tyrosine kinase inhibitor, to trastuzumab and chemotherapy. This conclusion seemed to be inconsistent with the results of NeoALTTO, a neoadjuvant trial that found a statistical improvement in pCR rate for the identical lapatinib-containing regimen. We address differences in the two trials that may account for discordant conclusions. However, we use the FDA meta-analysis to show that there is no discordance at all between the observed pCR difference in NeoALTTO and the observed HR in ALTTO. This underscores the importance of appropriately modeling the two endpoints when designing clinical trials. The I-SPY 2/3 neoadjuvant trials exemplify this approach.
• Nematollahi, S., Kaplan, S. J., Knapp, C. M., Ho, H., Alvarado, J., Viscusi, R., & Adamas-Rappaport, W. (2015). Introduction of a fresh cadaver laboratory during the surgery clerkship improves emergency technical skills. American Journal of surgery, 210(2), 401-403.e2.
  More info

  Student acquisition of technical skills during the clinical years of medical school has been steadily declining. To address this issue, the authors instituted a fresh cadaver-based Emergency Surgical Skills Laboratory (ESSL).
• Wecsler, J. S., Tereffe, W., Pedersen, R. C., Sieffert, M. R., Mack, W. J., Cui, H., Russell, C. A., Woods, R. R., Viscusi, R. K., Sener, S. F., & Lang, J. E. (2015). Lymph node status in inflammatory breast cancer. Breast cancer research and treatment, 151(1), 113-20. doi:10.1007/s10549-015-3367-6
  More info

  Positive lymph node status in breast cancer is known to be an adverse prognostic factor, but the effect of lymph node (LN) status in inflammatory breast cancer (IBC) has not been evaluated. This study was designed to investigate the association between lymph node status and overall survival (OS) in individuals with IBC. Using the Surveillance, Epidemiology, and End Results (SEER) 18 registry, we collected data on 761 patients diagnosed with non-metastatic IBC from 2004 to 2008. Survival analysis was performed using the Kaplan-Meier method. Cox proportional hazard regression was performed to evaluate univariate and multivariate associations between estrogen and progesterone receptor (ER/PR) status, treatment, and OS. Positive nodal status was associated with a significant decrease in OS (p 
• Lee, E., Lundberg, T., Rose, J., Ley, M., Waer, A., Livingston, R., Stopeck, A., Chalasani, P., Gonzalez, V., LeBeau, L., & Viscusi, R. K. (2014). A Retrospective Case Series and Literature Review of Primary Squamous Cell Cancer of the Breast. Journal of Surgery, S((2)), 2-4.
• Lang, J. E., Summers, D. E., Cui, H., Carey, J. N., Viscusi, R. K., Hurst, C. A., Waer, A. L., Ley, M. L., Sener, S. F., & Vijayasekaran, A. (2013). Trends in post-mastectomy reconstruction: a SEER database analysis. Journal of surgical oncology, 108(3), 163-8.
  More info

  This study was performed to investigate recent trends and factors associated with immediate breast reconstruction (IBR) using a large population-based registry. We hypothesized that rates of IBR have increased since passage of the Women's Health and Cancer Rights Act of 1998.
• Klein, R. L., Mook, J. A., Euhus, D. M., Rao, R., Wynn, R. T., Eastman, A. B., & Leitch, A. M. (2012). Evaluation of a hydrogel based breast biopsy marker (HydroMARK®) as an alternative to wire and radioactive seed localization for non-palpable breast lesions. Journal of surgical oncology, 105(6), 591-4.
  More info

  HydroMARK® is a newly available biopsy marker for image-guided needle biopsies of non-palpable breast lesions. Objective was to determine if the marker could be utilized independently for lesion localization using intra-operative ultrasound alone.
• Lewis, C. M., Bu, D., Sarode, V., Robinson, L., Wilson, K. S., Klein, R. K., Eng, C., & Euhus, D. M. (2012). The clinical consequences of hemizygosity across 2 MB of 10q23 are restricted to Cowden syndrome. Breast cancer research and treatment, 136(3), 911-8.
  More info

  Cowden syndrome is caused by germline mutations in PTEN and clinically characterized by hamartomas, macrocephaly, classic dermatologic stigmata, and an estimated 85 % lifetime risk of female breast cancer. A young woman with macrocephaly, tricholemmomas, AV malformations, and mammary papillomatosis was found to be hemizygous for PTEN in her germline DNA. Using MLPA, comparative genomic hybridization, and DNA sequencing, we identified a 2-Mb deletion in chromosome 10 spanning 344-kb centromeric and 1.7-Mb telomeric of PTEN. Her father who has a clinical history including macrocephaly, Hashimoto's thyroiditis, colonic polyposis, acral keratoses, and goiter was also found to have the same deletion. In benign breast tissue from the hemizygous female, PTEN protein expression was significantly reduced in luminal and stromal cells but present in the myoepithelium. Compared with a typical papilloma of the breast which had intense cytoplasmic PTEN staining, the majority of the patient's papilloma had significantly decreased PTEN expression while some cells had mislocalized perinuclear PTEN expression. In addition to PTEN, 22 other protein-coding genes were deleted including two predicted haploinsufficient genes and five additional genes that have previously been associated with hereditary predispositions to certain diseases. However, because all significant clinical features of the proband and her father are common to patients with genetic alterations in PTEN, the other 22 hemizygous protein-coding genes appear to be haplosufficient.
• Mook, J., Klein, R., Kobbermann, A., Unzeitig, A., Euhus, D., Peng, Y., Sarode, V., Moldrem, A., Leitch, A. M., Andrews, V., Teotia, S., & Rao, R. (2012). Volume of excision and cosmesis with routine cavity shave margins technique. Annals of Surgical oncology, 19(3), 886-91.
  More info

  Cavity shave margin (CSM) removal is a surgical technique that reduces re-excision rates. One criticism of this technique has been that negative margins are obtained primarily as a result of higher volumes of tissue removed. This study evaluates the volume of tissue removed in a group that underwent CSM versus one that underwent standard partial mastectomy (SPM) and explores cosmetic outcomes.
• Klein, R. L., Brown, A. R., Gomez-Castro, C. M., Chambers, S. K., Cragun, J. M., Grasso-Lebeau, L., & Lang, J. E. (2010). Ovarian cancer metastatic to the breast presenting as inflammatory breast cancer: a case report and literature review. Journal of Cancer, 1, 27-31.
  More info

  Background. Primary ovarian carcinoma with metastasis to the breast is rare, with only 39 cases reported in the current literature. Ovarian metastasis to the breast presenting as inflammatory breast carcinoma is even more infrequent, with only 6 cases reported.Case. We present a patient who developed metastatic inflammatory cancer of the breast from a stage IIIC papillary serous ovarian adenocarcinoma approximately 1 year after the original diagnosis. Pathologic analysis confirmed the origin of the tumor: a high-grade adenocarcinoma morphologically similar to the previously diagnosed ovarian cancer. In addition, the tumor was strongly positive on immunohistochemistry for CA-125, identical to the ovarian primary. The patient died of diffuse metastasis 5 months after the breast tumor was noted.Conclusion. Although ovarian metastasis to the breast presenting as inflammatory breast cancer is rare, it should be included in the differential diagnosis for any patient with a personal history of ovarian cancer. Accurate differentiation is necessary because treatment differs significantly for patients with ovarian metastasis to the breast, as compared with patients with primary inflammatory breast cancer. Ovarian metastasis to the breast confers a poor prognosis: patient survival ranged from 3 to 18 months, with a median survival of 6 months after the diagnosis of the breast metastasis.
• Viscusi, R. K., & Lang, J. (2010). Neratinib (HKI-272): An irreversible pan-ErbB inhibitor. Drugs of the Future, 35((8)), 621-8.

Presentations

• Kim, R. H., Viscusi, R. K., Collier, A. N., Hunsinger, M. A., Shabahang, M. M., Fuhrman, G. M., & Korndorffer, J. R. (2017, February 7-9). Learning Preferences of Surgical Residents: A Multi-Institutional Study. 12th Annual Academic Surgical Congress. Las Vegas, NV.
• Viscusi, R. K. (2017, April). Troubleshooting your Clerkship Presentation: Dealing with Grade Inflation. Association for Surgical Education Annual Meeting. San Diego, CA.
• Viscusi, R. K. (2017, Jan). Diagnosis and Treatment of Breast Cancer. Sun City Oro Valley Retirement Community Institute of Learning in Retirement. Oro Valley, AZ.
• Viscusi, R. K. (2017, October 24). Granulomatous Mastitis - Caring for the Patient with an Inflamed Breast: It’s Not Always Cancer. American College of Surgeons Clinical Congress. San Diego, CA: American College of Surgeons.
• Kim, R., Viscusi, R. K., Collier, A., & Kurtzman, S. (2016, April 12-16). Learning Preferences of Medical Students: A Multi-Institutional Study. Association for Surgical Education, 2016 Surgical Education Week. Boston, MA: Association for Surgical Education.
  More info

  Kim R, Viscusi, R, Collier A, Kurtzman S,; Learning Preferences of Medical Students: A Multi-Institutional Study; Association for Surgical Education, 2016 Surgical Education Week, Boston, MA; April 12-16, 2016.
• Viscusi, R. K. (2016, November). Rapid Fire Update on Breast Surgery. 2016 Annual Scientific Meeting. Tucson, AZ.
• Goyal, U., Livingston, R. B., Ley, M. L., Chalasani, P., Viscusi, R. K., Lebeau, L. G., & Gonzalez, V. J. (2015, June). Concurrent capecitabine and radiation therapy for high-risk breast cancer. ASCO annual meeting. Chicago, IL: American Society of Clinical Oncology.
• McCrary, H., Krate, J., Savilo, C., Ho, H., Viscusi, R. K., Ley, M., & Adamas-Rappaport, W. J. (2015, Oct. 4-8, 2015). Development of a Fresh Cadaver Model for Instruction of Ultrasound-Guided Breast Biopsy During the Surgery Clerkship: Pre-and Post-Test Results Among Third Year Medical Students. Clinical Congress 2015 - American College of Surgeons. Chicago, IL: American College of Surgeons.
  More info

  McCrary H, Krate J, Savilo C, Ho H, Viscusi RK, Ley M, Adamas-Rappaport A. "Development of a Fresh Cadaver Model for Instruction of Ultrasound-Guided Breast Biopsy During the Surgery Clerkship: Pre-and Post-Test Results Among Third Year Medical Students; Journal of the American College of Surgeons; Vol 221, Issue 4, Supp 1, Pg S50, Oct 2015 (Presented at Clinical Congress 2015 - American College of Surgeons; Chicago, IL; October 4-8, 2015)
• Stewart, D., Rappaport, D., Liu, N., Nematollahi, S., Viscusi, R. K., & Amini, R. (2015, Sept. 24 & 25). Use of a Fresh Cadaver Model to Teach Joint Aspiration: Pre-and Post-testing Evaluation. 2015 Midwest Regional SAEM Meeting. Toledo, OH: SAEM.
  More info

  Stewart Dandorf1, Douglas Rappaport2, Natalie Liu1, Saman Nematollahi3, Rebecca Viscusi1, Richard Amini1. 1University of Arizona, Tucson, AZ; 2Beth Israel Deaconess Medical Center, Boston, MA; 3New York Presbyterian - Columbia University, New York, NY; Use of a Fresh Cadaver Model to Teach Joint Aspiration: Pre-and Post-testing Evaluation; 2015 Midwest Regional SAEM Meeting; Toledo, OH; Sept. 24 & 25, 2015; Submitted
• Gallagher, K., Feldman, S., Barone, J., McGinness, M., Ochoa, D., Lang, J., Mammen, J., Barone, R., Viscusi, R. K., Lee, J., Adkins, L., Hardee, M., Korourian, S., & Klimberg, V. (2014, April 30 – May 4). Prospective Multicenter Trial Results of Excision Followed By Radiofrequency Ablation to Extend Intraoperative Margins. 13th Annual American Society of Breast Surgeons Meeting. Las Vegas, NV: American Society of Breast Surgeons.
  More info

  Gallagher K, Feldman S, Barone J, McGinness M, Ochoa D, Lang J, Mammen J, Barone R, Viscusi R, Lee J, Adkins L, Hardee M, Korourian S, Klimberg VS; Prospective Multicenter Trial Results of Excision Followed By Radiofrequency Ablation to Extend Intraoperative Margins; 13th Annual American Society of Breast Surgeons Meeting;Las Vegas, NV; April 30 – May 4, 2014; Submitted
• Yau, C., Wolf, D., Sanil, A., Chien, J., Wallace, A., Boughey, J., Yee, D., Tripathy, D., Viscusi, R. K., Hirst, G., Buxton, M., Hylton, N., Paoloni, M., Symmans, W., Esserman, L., Berry, D., Liu, M., Park, J., & Van't Veer, L. (2014, December 9-13). MammaPrint High1/High2 Risk Class as a Biomarker of response to Neratinib Plus Standard Neoadjuvant Therapy for Breast Cancer in the I-SPY 2 TRIAL. San Antonio Breast Cancer Symposium. San Antonio, TX.
  More info

  Yau C, Wolf D, Sanil A, Chien J, Wallace A, Boughey J, Yee D, Tripathy D, Viscusi RK, (…), Hirst G, Buxton M, Hylton N, Paoloni M, Symmans W, Esserman L, Berry D, Liu M, Park J, van’t Veer L; MammaPrint High1/High2 Risk Class as a Biomarker of response to Neratinib Plus Standard Neoadjuvant Therapy for Breast Cancer in the I-SPY 2 TRIAL; San Antonio Breast Cancer Symposium; San Antonio, TX; Dec. 9-13, 2014; Submitted
• Viscusi, R. K., Mook, J., Euhus, D., Rao, R., & Wynn, R. (2011, May 18). Evaluation of a Collagen Based Breast Biopsy Marker (HydroMARK®) as an Alternative to Wire and Radioactive Seed Localization for Non-Palpable Breast Lesions. 13th Annual UT Southwestern Department of Surgery Surgical Research Forum. Dallas, TX: UT Southwestern Department of Surgery Surgical Research.
  More info

  Klein R, Mook J, Euhus D, Rao R, Wynn R, et al; Evaluation of a Collagen Based Breast Biopsy Marker (HydroMARK®) as an Alternative to Wire and Radioactive Seed Localization for Non-Palpable Breast Lesions; 13th Annual UT Southwestern Department of Surgery Surgical Research Forum; Dallas, TX; May 18, 2011; Submitted
• Viscusi, R. K., Mook, J., Euhus, D., Rao, R., Wynn, R., & et al, . (2011, Feb 18-19). Evaluation of a Collagen Based Breast Biopsy Marker (HydroMARK®) as an Alternative to Wire and Radioactive Seed Localization for Non-Palpable Breast Lesions. North Texas Chapter - College of American Surgeons Annual Meeting. San Antonio, TX: North Texas Chapter - College of American Surgeons.
  More info

  Klein R, Mook J, Euhus D, Rao R, Wynn R, et al; Evaluation of a Collagen Based Breast Biopsy Marker (HydroMARK®) as an Alternative to Wire and Radioactive Seed Localization for Non-Palpable Breast Lesions; North Texas Chapter - College of American Surgeons Annual Meeting; San Antonio, TX; Feb 18- 19, 2011
• Viscusi, R. K., Gustafson, M., & Krouse, R. (2010, March 21-24). Synchronous Melanoma and Chronic Lymphocytic Lymphoma: A Case Report and Literature. 62nd Annual Southwest Surgical Congress. Tucson, AZ: Southwest Surgical Congress.
  More info

  Synchronous Melanoma and Chronic Lymphocytic Lymphoma: A Case Report and Literature; 62nd Annual Southwest Surgical Congress; Tucson, AZ; March 21-24, 2010

Poster Presentations

• R, P., M, W., M, S., D, S., Adamas-Rappaport, W., & Viscusi, R. K. (2017, April 28). Incorporating Technology Into Today’s Surgery Clerkship. Academy of Medical Education Scholars. Tucson, AZ.
• Coverley, C., Sherrow, D. R., Adamas-Rappaport, W. J., & Viscusi, R. K. (2016, April 12 - 16). Frequently Utilized Scholastic Resources in the Third Year Surgical Clerkship and Subsequent NBME Surgical Shelf Performances. Association for Surgery Education, 2016 Surgical Education Week. Boston, MA: Association for Surgical Education.
  More info

  Coverley C, Sherrow D, Adamas-Rappaport W, Viscusi R; Frequently Utilized Scholastic Resources in the Third Year Surgical Clerkship and Subsequent NBME Surgical Shelf Performances; Association for Surgical Education, 2016 Surgical Education Week, Boston, MA; April 12-16, 2016
• Albain, K., Leyland-Jones, B., Symmans, F., Paoloni, M., van 't Veer, L., Yau, C., Chien, A., Wallace, A., Forero-Torres, A., Yee, D., Kaplan, H., Nanda, R., Moulder, R., Haley, B., Elias, A., Boughey, J., Lang, J., DeMichele, A., Isaacs, C., , Kemmer, K., et al. (2015, 12/08/15 - 12/12/15). The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 Trial. San Antonio Breast Cancer Symposium. San Antonio, TX.
• Goyal, U., Livingston, R., Ley, M., Chalasani, P., Viscusi, R. K., Lebeau, L., & Gonzalez, V. (2015, May 29 – June 2). Concurrent Capecitabine and Radiation Therapy for High-Risk Breast Cancer. American Society of Clinical Oncology Annual Meeting. Chicago, IL: American Society of Clinical Oncology.
  More info

  Goyal U, Livingston R, Ley MB, Chalasani P, Viscusi RK, Lebeau L, Gonzalez VJ; Concurrent Capecitabine and Radiation Therapy for High-Risk Breast Cancer; American Society of Clinical Oncology Annual Meeting; Chicago, IL; May 29 – June 2, 2015; Submitted
• Lee, E. S., Ley, M. B., Viscusi, R. K., Waer, A. L., Borders, M. H., & Fitzpatrick, K. A. (2015, April 29). Use of Multiple Wire Localization for Breast Conservation Therapy. 14th Annual Association of Breast Surgeons Meeting. Orlando, FL.
• Segar, J., Baker, A., MacKerricher, W., Nagle, R., Livingston, R., Clarke, K., Ley, M., Viscusi, R. K., Gonzalez, V., LeBeau, L., & Chalasani, P. (2015, December 8-12). Clinicopathological and Molecular Characteristics of Pleomorphic Invasive Lobular Carcinoma. San Antonio Breast Cancer Symposium. San Antonio, TX: San Antonio Breast Cancer Symposium.
• Viscusi, R. K., Mcclenathan, J. H., Sherrow, D. R., Adamas-Rappaport, W., & Beliveau, L. (2015, April 21-25). Integrating a flipped classroom model into a surgery clerkship.. Association for Surgical Education, 2015 Surgical Education Week. Seattle, WA: Association of Surgical Education (ASE).
• Samuel, S., Viscusi, R. K., Waer, A., Hurst, C., Larson, E., Gonzalez, V., Chalasani, P., Lebeau, L., Livingston, R., & Ley, M. (2014, Dec 9-13). Nipple Sparing Mastectomy: Risks of Wound Complication in the Setting of Neoadjuvant Chemotherapy. 37th Annual San Antonio Breast Cancer Symposium. San Antonio, TX: San Antonio Breast Cancer Symposium.
  More info

  Samuel S, Viscusi RK, Waer A, Hurst C, Larson E, Gonzalez V, Chalasani P, Lebeau L, Livingston R, Ley MB; Nipple Sparing Mastectomy: Risks of Wound Complication in the Setting of Neoadjuvant Chemotherapy; 37th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; Dec. 9-13, 2014; Submitted
• Lee, E., Lundberg, T., Ley, M., Waer, A., Livingston, R., Stopeck, A., Chalasani, P., Gonzalez, V., LeBeau-Grasso, L., Rose, J., & Viscusi, R. K. (2013, Dec 10-14). Primary Squamous Cell Carcinoma of the Breast. 36th Annual San Antonio Breast Cancer Symposium. San Antonio, TX: San Antonio Breast Cancer Symposium.
  More info

  Lee E, Lundberg T, Ley M, Waer A, Livingston R, Stopeck A, Chalasani P, Gonzalez V, LeBeau-Grasso L, Rose J, Viscusi R; Primary Squamous Cell Carcinoma of the Breast; 36th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 10-14, 2013; Submitted
• Rugo, H., Olopade, O., DeMichele, A., Van’t Veer, L., Buxton, M., Hylton, N., Yee, D., Chien, A., Wallace, A., Viscusi, R. K., & Esserman, L. (2013, Dec 10-14). Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 Trial. 36th Annual San Antonio Breast Cancer Symposium. San Antonio, TX: San Antonio Breast Cancer Symposium.
  More info

  Rugo HS, Olopade O, DeMichele A, van’t Veer L, Buxton M, Hylton N, Yee D, Chien AJ, Wallace A, Viscusi RK, (…), Esserman L; Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 Trial; 36th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 10-14, 2013; Submitted
• Pandamouz, A., Delbridge, M., Cui, H., Viscusi, R. K., Ley, M., Borders, M., Fitzpatrick, K., Waer, A., & Lang, J. (2012, May 2-6). Impact of Pre-operative Breast MRI on Surgical Plan of Care for Breast Cancer Patients. American Society of Breast Surgeons 13th Annual Meeting. Phoenix, AZ: American Society of Breast Surgeons.
  More info

  Pandamouz A, Delbridge M, Cui H, Viscusi R, Ley M, Borders M, Fitzpatrick K, Waer A, Lang J; Impact of Pre-operative Breast MRI on Surgical Plan of Care for Breast Cancer Patients; American Society of Breast Surgeons 13th Annual Meeting; Phoenix, AZ; May 2-6, 2012; Submitted.
• Pederson, R., Sieffert, M., Tereffe, W., Cui, H., Woods, R., Viscusi, R. K., Grasso-Lebeau, L., & Lang, J. (2012, Dec 4-8). Lymph Node Status and Survival in Inflammatory Breast Cancer. 35th Annual San Antonio Breast Cancer Symposium. San Antonio, TX: San Antonio Breast Cancer Symposium.
  More info

  Pederson R, Sieffert M, Tereffe W, Cui H, Woods R, Viscusi R, Grasso-Lebeau L, Lang J; Lymph Node Status and Survival in Inflammatory Breast Cancer; 35th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; Dec 4-8, 2012; Submitted
• Vijayasekaran, A., Summers, D., Viscusi, R. K., Hurst, C., Biswas, A., Waer, A., & Lang, J. (2012, March 21-24). Effect of Hormone Receptor Status on Rates of Breast Reconstruction. Society of Surgical Oncology 65th Annual Cancer Symposium. Orlando, FL: Society of Surgical Oncology Cancer.
  More info

  Vijayasekaran A, Summers D, Viscusi R, Hurst C, Biswas A, Waer A, Lang J; Effect of Hormone Receptor Status on Rates of Breast Reconstruction; Society of Surgical Oncology 65th Annual Cancer Symposium; Orlando, FL; March 21-24,2012; Submitted
• Viscusi, R. K., Cui, H., Pockaj, B., Salinas, E., Brown, G., LeBeau-Grasso, L., Gonzalez, V., Lopez, A., Ley, M., & Lang, J. (2012, May 2-6). A Combined Institutional Review of Prognostic Factors in Locally Advanced and Inflammatory Breast Cancer. American Society of Breast Surgeons 13th Annual Meeting. Phoenix, AZ: American Society of Breast Surgeons.
  More info

  Viscusi R, Cui H, Pockaj B, Salinas E, Brown G, LeBeau-Grasso L, Gonzalez V, Lopez A, Ley M, Lang J; A Combined Institutional Review of Prognostic Factors in Locally Advanced and Inflammatory Breast Cancer; American Society of Breast Surgeons 13th Annual Meeting; Phoenix, AZ; May 2-6, 2012; Submitted
• Klein, R. R., Mook, J., Euhus, D., Rao, R., & Wynn, R. (2011, April 27- May 1). Evaluation of a Collagen Based Breast Biopsy Marker (HydroMARK®) as an Alternative to Wire and Radioactive Seed Localization for Non-Palpable Breast Lesions. American Society of Breast Surgeons 12th Annual Meeting. Washington, DC: American Society of Breast Surgeons.
• Mook, J., Viscusi, R. K., Leitch, M., Euhus, D., & Moldrem, A. (2011, March 2-5). Routine Cavity Shave Margin Excision Reduces Total Volume of Tissue Removed in Partial Mastectomy for Breast Cancer. Society of Surgical Oncology 64th Annual Cancer Symposium. San Antonio, TX.
  More info

  Mook, J, Klein R, Leitch M, Euhus D, Moldrem A, et al; Routine Cavity Shave Margin Excision Reduces Total Volume of Tissue Removed in Partial Mastectomy for Breast Cancer; Society of Surgical Oncology 64th Annual Cancer Symposium; San Antonio, TX; March 2-5 2011; Submitted.
• Mook, J., Viscusi, R. K., Leitch, M., Euhus, D., & Moldrem, A. (2011, May 18). Routine Cavity Shave Margin Excision Reduces Total Volume of Tissue Removed in Partial Mastectomy for Breast Cancer. 13th Annual UT Southwestern Department of Surgery Surgical Research Forum. Dallas, TX: UT Southwestern Department of Surgery Surgical Research Forum.
  More info

  Mook, J, Klein R, Leitch M, Euhus D, Moldrem A, et al; Routine Cavity Shave Margin Excision Reduces Total Volume of Tissue Removed in Partial Mastectomy for Breast Cancer; 13th Annual UT Southwestern Department of Surgery Surgical Research Forum; Dallas, TX; May 18, 2011; Submitted
• Viscusi, R. K., Cui, H., Salinas, E., LeBeau, L., & Lang, J. (2011, April 27- May 1). A Comparison of Prognostic Factors in Locally Advanced and Inflammatory Breast Cancer. American Society of Breast Surgeons 12th Annual Meeting. Washington, DC: American Society of Breast.
• Viscusi, R. K., Brown, A., Gomez-Casto, C., Chambers, S., & Cragun, J. (2009, March 4-7). Ovarian Cancer Metastatic to the Breast Presenting as Inflammatory Breast Cancer: A Case Report and Literature Review. 26th Annual Miami Breast Cancer Conference. Miami, FL: Miami Breast Cancer Conference.
  More info

  Klein R, Brown A, Gomez-Casto C, Chambers S, Cragun J, et al; Ovarian Cancer Metastatic to the Breast Presenting as Inflammatory Breast Cancer: A Case Report and Literature Review; 26th Annual Miami Breast Cancer Conference; Miami, FL; March 4-7 2009; Submitted.

Reviews

• Viscusi, R. K., Waer, A. L., & Neumayer, L. A. (2016. Selected Readings in General Surgery(pp Vol. 42 No. 1). Geriatrics & Palliative Care.
  More info

  Viscusi RK, Waer AL, Neumayer LA, reviewer. Selected Readings in General Surgery. 2016:42(1):e1. Accessed February 8, 2016. Review of: Chagpar AB, Killelea BK, Tsangaris TN, et al. Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer.

Others

• Viscusi, R. K., Chalasani, P., & Ley, M. (2017, October). Breast Cancer: Better Ways to Detect and Treat. Tucson Lifestyle.
• Viscusi, R. K. (2016, September). Subtyping and Survival of Invasive Ductal Carcinoma (IDC) among Hispanic and Non-Hispanic White (NHW) Women in Tucson, Arizona. ASCP 2016 Annual Meeting.
• R, D., MB, L., Viscusi, R. K., H, M., & V, G. (2015, Fall). Neoadjuvant Chemotherapy and Breast Conservation Therapy in Clinical T3 Breast Cancer. San Antonio Breast Cancer Symposium 2015.
• Viscusi, R. K. (2013, September). Breast Cancer. HealthBreak TV interview, KOLD-TV.